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Abstract
The 60 kDa heat shock protein (HSP60) has been reported to influence T-cell responses in two ways: as a ligand of toll-like
receptor 2 signalling and as an antigen. Here we describe a new mechanism of T-cell immuno-regulation focused on HSP60:
HSP60 is up-regulated and presented by activated T cells (HSP60 is an ergotope) to regulatory (anti-ergotypic) T cells.
Presentation of HSP60 by activated T cells was found to be MHC-restricted and dependent on accessory molecules - CD28,
CD80 and CD86. Anti-ergotypic T cells responded to T-cell HSP60 by proliferation and secreted IFNc and TGFb1. In vitro, the
anti-ergotypic T cells inhibited IFNc production by their activated T-cell targets. In vivo, adoptive transfer of an anti-
ergotypic HSP60-specific T-cell line led to decreased secretion of IFNc by arthritogenic T cells and ameliorated adjuvant
arthritis (AA). Thus, the presentation of HSP60 by activated T cells turns them into targets for anti-ergotypic regulatory T
cells specific for HSP60. However, the direct interaction between the anti-ergotypic T regulators (anti-HSP60) and the
activated T cells also down-regulated the regulators. Thus, by functioning as an ergotope, HSP60 can control both the
effector T cells and the regulatory HSP60-specific T cells that control them.
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Introduction
The 60 kDa HSP molecule (HSP60) has been found to induce
the down-regulation of immune inflammation. Vaccination with
self-HSP60 or its peptide epitopes can arrest the development of
type 1 diabetes (T1DM), spontaneous or induced, in non-obese
diabetic (NOD) mice [1,2,3] and in other mouse models [4];
HSP60 vaccination can also inhibit adjuvant arthritis (AA) in rats
[5,6,7]. In humans, spontaneous HSP60-specific T-cell responses
are associated with a relatively good prognosis in juvenile
rheumatoid arthritis [8,9], probably due to the activity of
HSP60-specific regulatory cells [10,11]. HSP60-based immuno-
regulation is being exploited clinically for the treatment of
autoimmune disorders; the administration of a peptide from
human HSP60 has been reported to halt b-cell destruction in
newly diagnosed T1DM patients [12,13] and to halt experimental
Sjo ¨gren’s syndrome [14]. An HSP60 peptide is also being
developed to treat human rheumatoid arthritis [7]. Thus is
important to characterize the immune regulatory mechanisms
triggered by HSP60.
HSP60 appears to affect immune inflammation by at least two
different mechanisms: as a ligand for innate immune receptors and
as an antigen recognized by adaptive immune receptors.
HSP60 can control T cells by innate receptor dependent
mechanisms. Soluble human HSP60 was found to directly signal
human T cells via toll-like receptor 2 (TLR2). The activation of
TLR2 dependant signalling on effector T cells has two
consequences: First, it inhibits the migration of T cells towards
the chemokine SDF-1 – irrespective of their antigen-specificity –
and so inhibits the general entry of T cells into inflammatory sites
[15]. Second, it down-regulates T-bet, NF-kB, and NFAT, and
up-regulates GATA-3, leading to decreased secretion of TNFa
and IFNc and enhanced secretion of IL-10 by the responding T
cells [16]. In addition to its direct effects on effector T cells,
HSP60-triggered activation of TLR2 signalling boosts the
suppressive activity of human CD4
+CD25
high T cells [17]. These
innate, TLR-2 mediated effects of soluble HSP60 can down-
regulate T-cell dependent inflammation.
HSP60 can also control T cells by T-cell receptor dependent
mechanisms. In T1DM, for example, vaccination with HSP60
epitopes activates HSP60-specific regulatory T cells that affect the
T-cell response to disease-associated antigens (insulin, glutamic
acid decarboxylase and HSP60 itself) by inducing a shift from the
secretion of INFc to IL-10 [3,18]; HSP60 vaccination induces a
similar cytokine shift in the response to the mycobacterial antigens
that trigger AA [6,7]. It has been proposed that HSP60-specific
regulatory T cells respond to HSP60 expressed and presented by
stressed tissue cells at sites of inflammation [19]. According to this
view, down-regulation of tissue inflammation is mediated through
a by-stander effect – the Th2 cytokines produced at the site by the
HSP60-specific T cells down-regulate the Th1 response of
adjacent effector T cells reacting to other tissue antigens [20,21].
We now report an additional mechanism by which HSP60
down-regulates inflammation: activated effector T cells up-
regulate HSP60 and present their own HSP60 epitopes to anti-
ergotypic regulatory T cells. Anti-ergotypic regulatory T cells
recognize peptides derived from molecules – ergotopes – expressed
by T cells primarily when they are activated [22,23]. Thus far,
several ergotopes have been defined: the CD25 molecule and the
TNFa receptor are examples [24,25]. Anti-ergotypic T cells,
detectable in humans [26,27] and in experimental animals [23],
are heterogeneous: they include CD4
+ and CD8
+ T-cell receptor
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4026ab (TCRab) and TCRcd T cells [26,27,28,29]. Most importantly,
anti-ergotypic T cells have been shown to down-regulate
damaging autoimmune inflammation in the model autoimmune
diseases experimental autoimmune encephalomyelitis (EAE)
[23,25] and AA [24].
Here we show that HSP60 fulfils the three defining properties of
a T-cell ergotope: activated T cells express HSP60; HSP60
epitopes are presented by T-cell MHC molecules and trigger
specific anti-ergotypic T cells; and the HSP60-specific anti-
ergotypic T cells can down-regulate pro-inflammatory effects of
effector T cells in vitro and in vivo. In other words, HSP60 is an
immune regulatory signal produced not only by stressed tissues,
but also by activated effector T cells in need of immune regulation.
Results
DNA vaccination with pHSP60 activates anti-ergotypic
responses
We have reported that DNA vaccination with the hsp60 gene
(pHSP60) or with its N-terminal fragments – constructs pI (aa 1–
130) or pII (aa 120–240)– induced HSP60-specific T cells and
inhibited the development of AA [6,7]. DNA vaccination with
mycobacterial HSP65 (pHSP65) also protected rats against AA
[30], but this vaccination was significantly less effective than was
vaccination with self-HSP60 [6]. Does protective HSP60 vaccina-
tion activate anti-ergotypic reactivity? To approach this question,
we studied the anti-ergotypic T-cell responses in rats vaccinated
with pHSP60, pI, pII, pHSP65 or pcDNA3, 26 days after the
induction of AA. Lymph node cells (LNC) of the vaccinated rats
were incubated with irradiated activated or resting A2b T cells, and
proliferative responses were measured to different numbers of A2b
stimulator cells. Figure 1A shows that vaccination with pHSP60
induced a proliferative anti-ergotypic T-cell response, which was
significantly (p,0.05) higher than that induced by pHSP65.
Moreover, vaccination with the pI or pII constructs of HSP60 also
induced a significant (p,0.05) anti-ergotypic response compared to
pcDNA3 (Figure 1B). Using neutralizing antibodies, we found that
the anti-ergotypic response induced by DNA vaccination included
both MHC-II (RT1.B) and MHC-I restricted T cells (Figure 1C).
Note that the pHSP60 DNA vaccine also increased the response
to resting A2b T cells, but to a lower extent than to activated A2b
T cells (Figure 1A). However, only activated A2b T cells induced
cytokine secretion – characterized by secretion of IFNc and
TGFb1, but not of IL-10 or IL-4 (Figure 1D).
Figure 1. DNA vaccination with HSP60 induces anti-ergotypic T cells. A and B. Anti-ergotypic proliferative response of LNC from rats
vaccinated with pcDNA3, pHSP65 or pHSP60 (A) or pcDNA3, pI or pII (B), taken 26 days after the induction of AA. Proliferative responses are
presented as the DCPM6SEM of quadruplicate cultures. * p,0.05 compared to the pHSP65 (A) or the pcDNA3 (B) groups. C. Monoclonal antibodies
to MHC-II/RT1.B, MHC-II/RT1.D or MHC-I were assayed for their ability to block the anti-ergotypic proliferative response. Results are presented as the
percent of inhibition of proliferation6SEM of quadriplicate cultures. D. Anti-ergotypic cytokine response of LNC taken from rats vaccinated with
pcDNA3, pHSP65, pHSP60, pI or pII 26 days after the induction of AA. IFNc (IFNg), TGFb1 (TGFb1), IL-10 and IL-4 were quantified in the culture
supernatants after 72 hr of stimulation with 10
5 activated or resting, irradiated, A2b cells per well. The results are presented as pg/ml6SEM of
triplicate cultures. Three independent experiments produced similar results.
doi:10.1371/journal.pone.0004026.g001
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response
Vaccination with the HSP60 peptide Hu3 (aa 31–50) can also
inhibit AA [7]. Does effective HSP60-peptide vaccination also
induce an anti-ergotypic response? Figure 2A shows that
vaccination with peptide Hu3 was significantly (p,0.05) more
effective in inducing an anti-ergotypic proliferative response than
was vaccination with the homologous, immunogenic Mt3 peptide
from mycobacterial HSP65. The anti-ergotypic proliferative
response induced by peptide Hu3 was also more focused in its
MHC-II restriction (Figure 2B); recall that HSP60 DNA
vaccination led to anti-ergotypic proliferative responses that
included both MHC-I and MHC-II restricted T cells
(Figure 1C). The anti-ergotypic T cells induced by Hu3 peptide
vaccination secreted IFNc and TGFb1, but not IL-10 or IL-4 in
response to activated A2b T cells (Figure 2C).
T-cell activation up-regulates HSP60 expression
The above results (Figures 1 and 2) suggested that the inhibition
of AA by HSP60 DNA or peptide vaccination was associated to
the induction of anti-ergotypic proliferative and cytokine responses
to activated, syngeneic T cells; but do epitopes of HSP60 function
as ergotopes? Is HSP60 up-regulated and presented on activated T
cells to anti-ergotypic T cells? To study this question, we compared
the expression of HSP60 in activated or resting T cells by western
blot. LNC were incubated for 1, 2 or 3 days with the T-cell
mitogen Con A, or left untreated. Cell lysates were prepared at the
end of the incubation, standardized by protein content, and
analyzed by western blot for the expression of HSP60. As a
positive control for the induction of HSP60, LNC were also heat
shocked for 30 minutes at 42uC and allowed to recover for 4 hr at
37uC. Figure 3A shows that T-cell activation with Con A or heat
shock triggered a similar increase in the expression levels of
HSP60. No differences in total protein content were seen when the
different samples were analyzed by PAGE-SDS (data not shown).
We also detected up-regulation of HSP60 following activation of
the T-cell clone A2b by its target peptide epitope Mt176-90 but
not by the control peptide Mt3 (Figure 3B); no differences in total
protein were seen when the samples were analyzed by PAGE-SDS
(data not shown). The up-regulation of HSP60 protein is in
agreement with previous studies done at the level of mRNA
expression [31], and demonstrates that T-cell activation by specific
antigen leads to the up-regulation of cellular HSP60.
Activated T cells stimulate HSP60-specific T cells
Are HSP60 epitopes actually presented by activated T cells? We
studied this question using HSP60-specific T-cell lines as probes
Figure 2. Vaccination with HSP60 peptide Hu3 induces anti-ergotypic T cells. A. Anti-ergotypic proliferative response of LNC from rats
vaccinated with PBS, Mt3 or Hu3 in IFA, taken 26 days after AA induction. Proliferative responses are presented as the DCPM6SEM of quadruplicate
cultures. * p,0.05 compared to the Mt3 group. B. Monoclonal antibodies to MHC-II/RT1.B, MHC-II/RT1.D or MHC-I were assayed for their ability to
block the anti-ergotypic proliferative response. Results are presented as the percent of inhibition of proliferation6SEM of quadruplicate cultures. C.
Anti-ergotypic cytokine response of LNC taken from rats vaccinated with PBS, Mt3 or Hu3 in IFA, 26 days after AA induction. IFNc (IFNg), TGFb1
(TGFb1), IL-10 and IL-4 were quantified in the culture supernatants after 72 hr of stimulation with 10
5 activated or resting, irradiated, A2b cells per
well. The results are presented as pg/ml6SEM of triplicate cultures. Three independent experiments produced similar results.
doi:10.1371/journal.pone.0004026.g002
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for MBP. Activated or resting A2b T cells were irradiated to
inhibit their proliferation, and their presentation of HSP60
epitopes was probed with the test T-cell lines. Figure 4A shows
that the Anti-HSP60 T cells proliferated upon incubation with
activated A2b; the response to resting A2b T-cells was significantly
lower. The reaction to HSP60 was specific; the Anti-MBP T cells
failed to respond to the A2b T cells, irrespective of their state of
activation. Thus, only the activated A2b T cells presented HSP60
epitopes recognizable by the Anti-HSP60 line. The proliferation of
the Anti-HSP60 line was restricted through the MHC-II/RT1.B
molecule (Figure 4C).
The 437-60 region of HSP60 (contained in the HSP60 peptide
designated p277) is an immunodominant T-cell epitope in the Lewis
rat [32]. We could therefore use an Anti-p277 T-cell line to
investigate whether activated A2b T cells presented the defined
HSP60 peptide epitope p277. Although less than the Anti-HSP60 T-
cell line (compare Figures 4A and 4B), the Anti-p277 T cells showed a
significant proliferation upon incubation with activated A2b T cells
(Figure 4B), but not with resting A2b T cells. This anti-ergotypic
proliferative response was MHC-II/RT1.B restricted (Figure 4C).
Thus, activated T cells can present a specific epitope of their up-
regulated HSP60 molecules – the p277 peptide epitope; that this
occurs in the absence of any other APC, suggeststhat activated T cells
can process and present epitopes of their own HSP60. Thus, T-cell
presentation of HSP60 can reveal the state of activity of a T cell.
To investigate how the anti-ergotypic response to HSP60 might
function, we analyzed the cytokines produced by Anti-HSP60 and
Anti-p277 T cells in response to either activated or resting A2b T
cells. Figure 4D shows that both the Anti-HSP60 and Anti-p277
T-cells secreted relatively small amounts of IFNc and relatively
high amounts of TGFb1 upon stimulation with activated A2b T
cells only. The T cells did not secrete IL-10 or IL-4.
The activation of HSP60-specific anti-ergotypic T cells
requires co-stimulation
Complete T-cell activation is achieved when TCR-mediated
signaling is reinforced by signals originating from co-stimulatory
molecules such as CD28. CD28 interacts with CD80 and CD86
molecules displayed on the surface of APC [33]. Activated T cells
[34,35] and activated A2b [28] express CD80 and CD86 molecules
on their surface. We therefore studied the need for CD80, CD86
and CD28 in the activation of HSP60-specific T cells by activated T
cells. LNC prepared from pHSP60 vaccinated rats, or Anti-HSP60
T cells, were stimulated with irradiated A2b T cells in the presence
of blocking antibodies to CD80, CD86 or CD28. Figure 5 shows
that incubation with each one of these antibodies produced a
significant inhibition in the anti-ergotypic response of HSP60-
specific T cells. Hence, co-stimulation by way of CD80, CD86 and
CD28 appears to be required for the activation of anti-ergotypic
HSP60-specific T cells by activated T cells.
HSP60-specific anti-ergotypic T cells ameliorate AA
If HSP60-specific anti-ergotypic T cells are indeed regulatory,
then it should be possible to inhibit inflammatory disease by
adoptively transferring them. We tested the effects of Anti-p277 T
cells on AA by transferring 10
7 cells to rats 3 days before the active
induction of AA. As a control, we used the Anti-MBP T-cell line.
The rats were scored for signs of arthritis, and the hind paw
diameter was measured with a caliper on day 26, the peak of AA
[36]. Figure 6 shows that the recipients of the Anti-p277 cells
showed a significant reduction in the signs of AA, both in terms of
arthritis score and of limb swelling. The Anti-MBP T cells had no
effect on the progression of AA (Figure 6).
The arthritogenic T cells that drive AA have a Th1 phenotype.
Accordingly, lymph node T cells from rats suffering from AA rats
secrete high levels of IFNc in response to in vitro stimulation with the
Mt176-90 peptide [6], containing the pathogenic 180-88 T-cell
epitope of the mycobacterial 65 kDa HSP [37]. The inhibition of AA
achieved by vaccination with HSP60 or its peptides is reported to be
associated with a reduction in INFcproduction induced by Mt176-90
[6,7]. We therefore isolated LNC from rats adoptively transferred
with Anti-p277 or Anti-MBP T cells, and studied the secretion of
IFNc upon stimulation with Mt176-90. Figure 7C shows that the
transfer of Anti-p277 T cells led to a significant reduction in the
secretion of IFNc in response to the AA target peptide Mt176-190.
Thus, HSP60-specific T cells, demonstrating anti-ergotype activity,
down-regulate IFNc secretion by the candidate pathogenic T cells at
the time they adoptively down-regulate AA.
HSP60-specific anti-ergotypic T cells modulate effector T-
cell IFNc in vitro
The results obtained in the AA model demonstrated that anti-
ergotypic HSP60-specific T-cells can control effector T cells by
Figure 3. T-cell activation up-regulates cellular levels of HSP60.
A. LNC were stimulated with Con A for 24, 48 or 72 hr, subjected to a
30 minutes 42uC heat shock (HS) or kept at 37uC (None). Cell lysates
were prepared and HSP60 expression was analyzed by western blot
with specific antibodies, and quantified (in arbitrary units). B. A2b T-cells
were stimulated with various concentrations of the target peptide
Mt176-90, a control peptide (Mt3) for 72 hr, or with medium alone
(None). Cell lysates were prepared and HSP60 expression was analyzed
by western blot with specific antibodies, and quantified (in arbitrary
units). Two independent experiments produced similar results.
doi:10.1371/journal.pone.0004026.g003
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specific anti-ergotypic T cells, we tested whether these T cells
might be able to directly regulate in vitro the IFNc secretion of
LNC taken from rats on day 26, at the peak of AA. LNC of rats
with actively induced AA were prepared and activated with
Mt176-90 in the presence of the Anti-p277 anti-ergotypic T-cell
line, or in the presence of the control Anti-MBP T-cell line. T cells
reactive with Mt176-90 have been shown to transfer AA to
irradiated naı ¨ve Lewis rats [38]. Co-incubation with the Anti-p277
line, but not with the Anti-MBP line, led to a significant decrease
in the secretion of IFNc (Figure 7). We did not detect a
concomitant induction of IL-10 (not shown). Thus, anti-ergotypic
T cells can directly control in vitro the arthritogenic T-cell IFNc
cytokine response.
HSP60-specific regulators become anergic while
regulating activated T cells
We have shown in the previous sections that HSP60-specific
anti ergotypic T cells can recognize and down-regulate arthrito-
genic T cells, in vitro and in vivo. However, any regulatory
mechanism has to be regulated; uncontrolled down-regulation of
immunity would be as detrimental to the organism as uncontrolled
Figure 4. MHC class II-restricted recognition of activated T cells by HSP60-specific T-cells. A. Anti-ergotypic proliferative response of Anti-
HSP60 or Anti-MBP T cell lines. Proliferative responses are presented as the DCPM6SEM of quadruplicate cultures. B. Anti-ergotypic proliferative
response of Anti-p277 or Anti-MBP T cell lines. Proliferative responses are presented as the DCPM6SEM of quadruplicate cultures. C. Monoclonal
antibodies to MHC-II/RT1.B, MHC-II/RT1.D or MHC-I were assayed for their ability to block the anti-ergotypic proliferative response of the Anti-HSP60
and the Anti-p277 T cell lines. Results are presented as the percent of inhibition of proliferation6SEM of quadruplicate cultures. D. IFNc (IFNg), TGFb1
(TGFb1), IL-10 and IL-4 were quantified in the culture supernatants after 72 hr of stimulation of the Anti-MBP, Anti-p277 or Anti-HSP60 T cell lines with
10
5 activated or resting, irradiated, A2b cells per well. The results are presented as pg/ml6SEM of triplicate cultures. Three to five independent
experiments produced similar results.
doi:10.1371/journal.pone.0004026.g004
Figure 5. The activation HSP60-specific anti-ergotypic T cells
requires co-stimulation. Monoclonal antibodies to CD28, CD80 or
CD86, or a control IgG (Control), were assayed for their ability to block
the anti-ergotypic proliferative response of Anti-HSP60 T-cells (Line) or
of LNC prepared from pHSP60-vaccinated rats (LNC). Results are
presented as the percent of inhibition of proliferation6SEM of
quadruplicate cultures. Three independent experiments produced
similar results.
doi:10.1371/journal.pone.0004026.g005
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of HSP60-specific anti-erogotypic T cells by activated T cells
might itself affect the regulators. In other words, might the anti-
ergotypic HSP60-specific T-cell lines be affected differently by
seeing their HSP60 epitopes presented by activated T cells
compared to recognizing HSP60 presented by classical APC? To
study this possibility, we incubated the Anti-p277 line for 3 days
with either irradiated APC and p277 peptide or with irradiated,
activated A2b T cells. The Anti-p277 T cells were then recovered
from the cultures, maintained for 4 additional days in culture
without APC or A2b T cells, and then stimulated with APC and
p277 peptide, with mitogenic Con A or immobilized anti-TCR.
Figure 8 presents the outcome. It can be seen that the Anti-p277 T
cells, following co-culture with APC and p277 could still respond
to a second stimulation with APC and p277 or with mitogenic
aTCR or ConA; however, previously co-culturing the anti-p277
line with activated A2b T cells rendered the Anti-p277 line
anergic; the line now failed to proliferate in response to APC and
p277 or to either of the two mitogens (Figure 8A). The Anti-p277
T cells could still secrete IFNc (Figure 8B) but not TGFb1, IL-10
or IL-4, despite their failure to proliferate. The Anti-p277 line
cells, however, went on to die in vitro after their exposure to the
activated A2b T cells. Thus, it appears that the interaction of anti-
ergotypic T-cell lines with their target activated effector T cells
leads to anergy and loss of the anti-ergotypic T cells; activated
effector T cells and regulator T cells can down-regulate each
other. In contrast, anti-ergotypic T cells can be maintained in
culture by APC and specific peptide antigen [22].
Discussion
The present study extends the role of HSP60 in immune
regulation; HSP60, as we show here, can also function in anti-
ergotypic T-cell regulation. Anti-ergotypic T cells have been
identified as a population of regulatory T cells expanded by T-cell
vaccination regimes [22,28]. T cell vaccination has shown
promising results in clinical trials that studies its potential as a
therapy for multiple sclerosis and rheumatoid arthritis [39,40,41].
Notably, T cell vaccination induces two types of anti-ergotypic
regulatory T cells: CD4
+CD25
highFoxp3
+ regulatory T cells and
also CD4
+CD25
highFoxp3
2 regulatory T cells [39,40]. The anti-
ergotypic T cells reactive with HSP60 described in this manuscript
Figure 6. HSP60-specific anti-ergotypic T-cells control arthrito-
genic T-cells in vivo. A and B. Anti-MBP or Anti-p277 T cells were
injected ip into naı ¨ve Lewis rats and three days later AA was induced.
Twenty-six days after AA induction, at the peak of AA, the AA clinical
score (A) and the hind paw diameter (B) were determined. The bars
represent the mean values 6 SEM for each group of 8 rats. C. LNC were
collected on day 26 after AA induction and the secretion of IFNc upon
stimulation with Mt176-90 was studied. The results are presented as pg/
ml6SEM of triplicate cultures. Three independent experiments pro-
duced similar results. * p,0.05 and ** p,0.005 compared to the Anti-
MBP group.
doi:10.1371/journal.pone.0004026.g006
Figure 7. HSP60-specific Anti-ergotypic T-cells control arthri-
togenic T-cells in vitro. LNC from Mt immunized rats (2.5610
5 per
well) were activated with Mt176-90 for 72 hr in the presence of Anti-
p277 or Anti-MBP T-cells (5610
4 per well). The secretion of IFNc was
determined by ELISA, the results are presented as pg/ml6SEM of
triplicate cultures. The differences between the groups were significant
(p,0.05) for antigen concentrations higher than 0.1 mg/ml. Three
independent experiments produced similar results.
doi:10.1371/journal.pone.0004026.g007
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and are therefore similar to the CD4
+CD25
highFoxp3
2 T cells
described by Zhang and coworkers [39,40]. The association of
these anti-ergotypic regulatory cells with a beneficial effect of T
cell vaccination on multiple sclerosis and rheumatoid arthritis
[39,40,41], demonstrates the importance of this regulatory cell
population as a target for human immunotherapy. The results
presented here demonstrate that HSP60 is an ergotope, shedding
light on two separate but overlapping issues: the various roles of
HSP60 in immune regulation and the nature of anti-ergotypic T
regulators.
Vaccination with HSP60 DNA or peptide, previously shown to
down-regulate AA [6,7], can activate various types of anti-ergotypic
responses (Figures 1 and 2). Similarly to what we observed for DNA
vaccination with the CD25 ergotope [28], DNA vaccination with
HSP60 or its fragments induced both MHC-I and MHC-II
restricted anti-ergotypic T cells (Figure 1). Hu3 peptide vaccination,
conversely,onlyactivated an MHC-II restrictedresponse (Figure 2).
Therefore we can conclude that activated T cells process their
endogenous HSP60 by both the MHC-I and the MHC-II pathways
of antigen presentation. Moreover, our results suggest that the anti-
ergotypic T-cell population responsive to HSP60 is heterogeneous,
and different methods of HSP60 vaccination (DNA or peptides)
might be used to expand particular HSP60-specific anti-ergotypic
subpopulations.
It is intriguing that ergotopes such as HSP60 and CD25 are
presented by MHC-II molecules. Peptides derived from endoge-
nous antigens are usually MHC-I restricted, while MHC-II
molecules mainly present peptides provided by the endocytic
pathway of antigen processing [42]. The processing and
presentation of endogenous antigens via by the MHC-II pathway
has been extensively reported and is thought to result from active
mechanisms of autophagy operating in T cells [43,44]. However,
the existence of natural anti-ergotypic regulatory T cells reactive
with HSP60 differentiates the MHC presentation of an ergotope
from the presentation of other self-antigens: activation-triggered
expression of HSP60 turns T cells into targets of HSP60-specific
anti-ergotypic regulation. It remains to be seen whether HSP60
epitopes are also presented by other, non-classical MHC
molecules. Q1a, for example, is a non-classical MHC-I molecule
expressed on T cells that can present endogenous epitopes to
regulatory T cells of the CD8
+ type [45]. These Q1a-mediated
interactions have been shown to control EAE through a T-cell
network that involves both CD4
+ and CD8
+ T cells [46,47]; it is
possible that the Q1a regulatory network also includes anti-
ergotypic T cells reactive to HSP60.
HSP60 is also a target of natural T and B cell autoreactivity.
Natural antibodies to HSP60 are detectable in the serum of
healthy humans [48,49] and mice [50]; the IgG isotype of these
antibodies reveals the activation of helper HSP60-specific T cells.
Actually, human cord blood contains a high frequency of T cells
responsive to HSP60, and repertoires of healthy humans contain T
cells reactive to self-HSP60 [51]. The prevalence of autoimmunity
to HSP60 suggests that it serves as a component of the
immunological homunculus [52,53], and mediates an anti-
inflammatory effect [19]. Indeed, T-cell reactivity to HSP60 is
Figure 8. Anti-ergotypic HSP60-specific T cells become anergic after interacting with activated T cells. Anti-ergotypic Anti-p277 T cells
were stimulated for 3 days with irradiated, activated A2b cells (A2b) or with irradiated APC fed with the p277 peptide (APC). The Anti-p277 T cells
were maintained for 4 additional days in culture, and stimulated with APC and p277 peptide, Con A or immobilized anti-TCR (aTCR) antibodies. T-cell
proliferation (A) and IFNc (B) release were measured after 3 days. The proliferative responses are presented as the DCPM (6SEM) (A), and the IFNc as
pg/ml6SEM (B) of triplicate cultures. Three to five independent experiments produced similar results.
doi:10.1371/journal.pone.0004026.g008
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the administration of a peptide of HSP60 to newly diagnosed
patients with T1DM can arrest the autoimmune destruction of b-
cells and induce a Th1 to Th2 shift in the diabetogenic T cells
[13]. Autoimmunity to HSP60, naturally acquired or induced by
vaccination, bodes well for healthy immune regulation.
How might HSP60-specific anti-ergotypic T cells control the
arthritogenic T cells? The anti-inflammatory properties of HSP60-
specific T cells are thought to rely on a local by-stander effect
exerted on other T cells via regulatory cytokines such as IL-10 and
TGFb1 [55,56]. We have found (Figures 1, 2 and 4), that the
HSP60-specific anti-ergotypic T cells secrete TGFb1, a cytokine
with immuno-modulatory functions [55]. Indeed, the HSP60-
specific anti-ergotypic T cells controlled the activity of arthrito-
genic T cells both in vivo (Figure 6) and in vitro (Figure 7). We
propose that upon recognition of their target HSP60 epitopes
within MHC molecules on the surface of activated T cells, the
anti-ergotypic T cells can modulate the pro-inflammatory activity
of effector T cells via the secretion of TGFb1, and perhaps other,
yet undetected regulatory cytokines. Note that upon transfer of
anti-ergotypic HSP60-specific T cells, we detected a decrease in
the activity of the arthritogenic T cells that secrete IFNc (Figure 6).
However, we did not detect a concomitant increase in the number
of IL-10 secretors, as we have previously described upon
vaccination with DNA vaccines coding for HSP60 or its fragments
[6,7], or following vaccination with the HSP60 peptide Hu3 [7].
Hence, the participation of HSP60 in anti-ergotypic regulatory
networks might only account for some, but not all, of the
regulatory activities of HSP60-specific T cells. Indeed, it has been
recently shown that HSP60 can have direct anti-inflammatory
effects on human T cells which are TLR2-dependant: free HSP60
can inhibit T-cell migration towards the inflammatory chemokine
SDF-1A [15] and modify the levels of transcription factors
involved in T-cell polarization, leading to decreased secretion of
TNFa and IFNc and enhanced secretion of IL-10 [16,17].
Finally, the present study indicates that HSP60-specific anti-
ergotypic regulatory T cells can be down-regulated as a result of
their interaction with their target T cells (Figure 8). Indeed, the
induction of a strongly arthritogenic T-cell effector response
leading to adjuvant arthritis was found to suppress the anti-
ergotypic regulator response; this down-regulation of the regula-
tors by the effectors could be overcome by vaccinating the rats
with an ergotope, CD25 [24]. Thus, the magnitude of an immune
response can be influenced decisively by a dynamic balance
between regulators and effectors [28]. In this light, we can view the
complex roles of HSP60 in immuno-regulation: HSP60 facilitates
the recognition and control of activated T cells via anti-ergotypic
interactions, and this regulatory interaction also down-regulates
the activity of the HSP60-specific regulators. The regulatory
molecules on activated T cells that down-regulate the anti-
ergotypic regulators remain to be discovered; however, it has been
reported that mutual interactions between T cells (T-T interac-
tions) can induce T-cell anergy [57,58]. Thus, the numbers of
regulatory T cells reactive to HSP60 might be positively influenced
by the presentation of HSP60 by professional APC and negatively
influenced by the presentation of HSP60 by activated T cells [59];
regulators, too, need regulation [22].
In conclusion, our results show that the varied regulatory
mechanisms mediated by HSP60 are complex indeed; not only
does the immune system use innate and adaptive receptors to
respond to HSP60 expressed in situ by the tissues and in body fluids
[60], we can now conclude that the immune system uses its own
HSP60 expressed on activated T cells as a marker that reflects
their functional state and their need of regulation.
Materials and Methods
Rats
Female Lewis rats were raised and maintained under pathogen-
free conditions in the Animal Breeding Center of the Weizmann
Institute of Science. Experiments were carried out under the
supervision and guidelines of the Animal Welfare Committee. The
rats were 1–2 months old at the start of the experiments.
Antigens, peptides, antibodies and adjuvants
M. tuberculosis (Mt) strain H37Ra was obtained from Difco
(Detroit, MI, USA). Mt purified protein derivative (PPD) was
provided by the Statens Seruminstitut (Copenhagen, Denmark).
Recombinant mycobaterial 65 kDa HSP (HSP65) was kindly
provided by Dr. Ruurd van der Zee (Institute of Infectious
Diseases and Immunology, Faculty of Veterinary Medicine,
Utrecht, The Netherlands). Recombinant HSP60 was prepared
as described [6]. Guinea pig myelin basic protein (MBP) was
purchased from Sigma (Rehovot, Israel). Two HSP65 peptides
were used: Mt176–190 (aa 176–190) EESNTFGLQLELTEG [61]
and Mt3 (aa 5–24) AYDEEARRGLERGLNALADA [7]. The
Mt176-90 peptide used in this work includes the 180–188 epitope
[37]. Two peptides derived from HSP60 were used: p277 (aa 437–
460) VLGGGCALLRCPALDSLTPANED and Hu3 (aa 31–50)
KFGADARALMLQGVDLLADA. Peptides were synthesized by
a standard Fmoc procedure, purified by reverse-phase HPLC and
their compositions confirmed by aa analysis. Concanavalin A (Con
A) was purchased from Sigma. Incomplete Freund’s Adjuvant
(IFA) was purchased from Difco.
A monoclonal antibody reactive to rat TCR (clone R73) was
purified by us from the hybridoma. Monoclonal antibodies to
MHC class-I (MHC-I), MHC class-II RT1.B (MHC-II/ RT1.B),
MHC class-II RT1.D (MHC-II/RT1.D), CD28, CD80 and
CD86 were purchased from Serotec (Oxford, UK). Purified rabbit
anti-human HSP60 polyclonal IgG antibodies were provided by
Dr Gabriel Nussbaum (Department of Immunology, The
Weizmann Institute of Science, Israel).
T-cell lines and clones
T-cell lines were raised and expanded as described [38]. Three
Lewis rat T-cell lines were used in our experiments: Anti-HSP60,
raised against recombinant human HSP60 (human HSP60 is 97%
identical to rat HSP60 at the aa level, data not shown); Anti-p277,
raised against the p277 peptide of human HSP60 (96% identical
its rat counterpart at the aa level, data not shown) and Anti-MBP,
raised against guinea pig MBP. For ergotypic stimulation, we used
the A2b T-cell clone, specific for the 180–188 epitope of HSP65
[37]; similar results were obtained when other rat T-cell clones
were used as targets (data not shown). A2b expresses MHC-I
molecules constitutively and CD80, CD86 [62] and MHC-II
molecules (not shown) upon activation, and can present peptide
epitopes to T cells [63]. Activated A2b cells were used on day 3 of
their stimulation, and resting A2b cells were used on day 14–16 of
their rest cycle, unless stated otherwise.
DNA and peptide vaccination
The vectors containing the full-length cDNA of the human
hsp60 gene (pHSP60) or the cDNA corresponding to aa 1–140 (pI)
or aa 130–260 (pII) have been previously described [6,7]. The
vector coding for mycobacterial HSP65 (pHSP65) was kindly
provided by Dr. Douglas Lowrie (Medical Research Council,
London, UK) [30]. The empty vector pcDNA3 was used as a
DNA vaccination control.
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pretreatment with cardiotoxin (Sigma) as previously described
[36]. Briefly, rats were vaccinated in the quadriceps three times (on
days 240, 226 212 relative to AA induction) with 150 mgo f
pcDNA3, pHSP65 or pHSP60. Endotoxin levels were checked by
the Limulus amoebocyte lysate assay and found always to be under
acceptable levels for in vivo use (less than 0.02 EU/mg DNA).
Female Lewis rats were immunized intraperitoneally (ip) with a
single dose of 100 mg of peptide emulsified in IFA. AA was
induced 12 days after the completion of vaccination with DNA or
peptide.
AA Induction and Assessment
AA was induced using heat-killed Mt strain H37Ra (Difco)
suspended in IFA, as described [6]. The day of AA induction was
designated as day 0. Disease severity was assessed by direct
observation of all 4 limbs in each animal. A relative score between
0 and 4 was assigned to each limb, based on the degree of joint
inflammation, redness and deformity; thus the maximum possible
score for an individual animal was 16. Arthritis was also quantified
by measuring hind limb diameter with a caliper. Measurements
were taken on the day of the induction of AA and 26 days later, at
the peak of AA [6]; the results are presented as the mean6SEM of
the difference between the values for hind limb diameter taken on
days 0 and 26.
Anti-ergotipic T-cell proliferation assay
T-cell lines or lymph node cells (LNC, prepared from inguinal
and popliteal lymph nodes) were cultured in quadruplicates,
2.5610
5 per well, in round-bottom microtiter wells (Nunc,
Roskilde, Denmark). Activated or resting A2b stimulator cells
were irradiated (5000 R) and added to the test cultures in 2-fold
dilutions, starting from 10
5 cells per well, with no other APC. Con
A (1.25 mg/ml) was used as a positive control for T-cell
proliferation, and in some experiments the cells were activated
with immobilized anti-TCR antibodies as described [64].
Monoclonal antibodies, 10 mg/ml, were added where indicated
to test for MHC restrictions or co-stimulation requirements of the
anti-ergotypic T cells. Cultures were incubated for 72 hr at 37uC
in 7% CO2, and pulsed for the last 16 hr with 1 mCi/well of
[methyl-
3H]-thymidine (Amersham, Buckinghamshire, UK). The
cultures were harvested and cpm were determined using a beta
counter. The DCPM was computed as the difference between the
mean cpm of wells containing activated or resting A2b stimulator
cells to control wells cultured with medium alone.
Cytokine assays
Supernatants were collected after 72 hr of stimulation with test
antigens or stimulator cells. Pharmingen’s OPTEIA IL-10, IL-4
and IFNc kits (Pharmingen, San Diego, USA) and the TGFb1
EmaxH ImmunoAssay System (Promega, Madison, USA) were used
to quantify cytokine release to culture supernatants, as previously
described [6]. The lower limits of detection for the experiments
described in this paper were 15 pg/ml for TGFb1, IL-10, IL-4
and IFNc.
Western blotting
Cell lysates of resting or activated T cells were prepared by
treatment for 15 minutes in the following lysis buffer: NP40 1%,
NaCl 0.9%, Tris 50 mM, EDTA 1 mM, PMSF 0.4 mM,
pepstatin A 4 mg/ml, leupeptin 4 mg/ml and aprotinin 4 mg/ml.
The lysates were centrifuged for 15 min at 14000 rpm and the
protein concentration in the supernatant was determined using a
BCA protein assay kit (Pierce, Rockford, IL, USA). The lysates
were subjected to PAGE-SDS using a mini-gel apparatus (Bio-Rad
Laboratories, Hercules, CA); 100 mg of each sample were loaded
per well. Two identical gels were run each time in parallel: one gel
was stained with Coomassie Brilliant Blue R-250 according to the
manufacturer’s protocol (Bio-Rad) and the other was electro-
transferred to nitrocellulose membranes (Schleicher and Schuell,
Dassel, Germany).
The nitrocellulose membranes were washed with PBS and then
blocked for 1 hr with 2% bovine serum albumin (Sigma), 2.5%
milk powder (Bio-Rad), Tris (Sigma) pH 7.5 10 mM, NaCl
150 mM and 0.02% thimerosal (Sigma). After washing with
PBS/Tween 20 (PBST; 0.02%, Sigma), the membranes were
incubated in blocking solution for 2 hr with HSP60-specific
polyclonal antibodies. The membranes were washed with PBST
and incubated with a peroxidase-conjugated goat anti-rabbit IgG
(Jackson Immuno-Research, West Grove, PA) at a 1/10000
dilution in blocking solution for 1 hr. Finally, the membranes were
developed using the Western Blotting Luminol Reagent (Santa
Cruz Biotechnology Inc., Santa Cruz, California, USA), exposed
to X-ray film and quantified using the NIH Image 1.63 program
(National Institutes of Health, USA). Size was determined using
pre-stained broad-range protein standard markers (Bio-Rad).
Adoptive transfer of anti-ergotypic T cells
Anti-p277 or Anti-MBP T cells were activated for 3 days in
culture. Blast cells were isolated using a LymphoPrep gradient
(Nycomed, Oslo, Norway), washed, and 5610
6 cells per rat were
injected ip. Three days later, AA was induced.
Statistical significance
The InStat 2.01 program was used for statistical analysis.
Student’s t-test and the Mann-Whitney test were carried out to
assay significant differences between the different experimental
groups.
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